acute deep venous thrombosis of lower extremities
Conditions
Interventions
Treament group:bivarudine
Control group:low molecular weight heparin
Sponsors
Guangdong Provincial People's Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age range: 18-80 years old. It meets the diagnostic criteria of acute iliac, femoral and popliteal vein thrombosis (primary) disease: imaging examination found thrombus formation in deep vein of lower limb. The patients voluntarily participated in the study, signed a written informed consent, and were willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1) Patients who received anticoagulant therapy within the previous 4 weeks; 2) Patients who have had any major surgery or history of severe trauma within 4 weeks prior to the examination; 3) Patients with contraindications or allergies to the use of anticoagulants, contrast agents and thrombolytic drugs had brain, gastrointestinal, etc., in the past 3 months History of active bleeding or cerebral infarction; 4) Patients with high alanine aminotransferase (ALT) or aspartate aminotransferase (AST) were examined At or equal to 1.5 times of the upper limit of normal value stipulated by the Center, or the endogenous creatinine clearance rate (CCr) is greater than the limit of the Center The upper limit of normal values; 5) Total white blood cell count (WBC) was greater than 10.0X109/L or less than 1.0X09/L; 6) The patient has a history of immunodeficiency diseases (such as HIV, etc.), or a history of cancer, malignancy, or autoimmune diseases, or serious cardiovascular or cerebrovascular diseases, or other diseases that may significantly reduce life expectancy; 7) Have a history of any medical conditions that may affect protocol compliance (e.g. severe mental disorder, cognitive impairment, medication) Substance abuse or addiction, etc.); 8) Pregnant or lactating women, or those who are fertile and unwilling/unable to take effective contraceptive measures; 9) Those who are known to be allergic to the ingredients used in this study; 10) Have participated in any drug clinical trials within 6 months before the examination; 11) Patients judged unsuitable for this study by the investigator;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| thrombolysis rate;diameter of the legs;international normalized ratio;activated partial thromboplastin time;D-Dimer; | — |
Countries
China
Contacts
Public ContactJinsong Wang
Guangdong Provincial People's Hospital
Outcome results
None listed